147 related articles for article (PubMed ID: 15456248)
1. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
Tavares FX; Deaton DN; Miller AB; Miller LR; Wright LL; Zhou HQ
J Med Chem; 2004 Oct; 47(21):5049-56. PubMed ID: 15456248
[TBL] [Abstract][Full Text] [Related]
2. Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.
Tavares FX; Deaton DN; Miller LR; Wright LL
J Med Chem; 2004 Oct; 47(21):5057-68. PubMed ID: 15456249
[TBL] [Abstract][Full Text] [Related]
3. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
4. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
Barrett DG; Boncek VM; Catalano JG; Deaton DN; Hassell AM; Jurgensen CH; Long ST; McFadyen RB; Miller AB; Miller LR; Payne JA; Ray JA; Samano V; Shewchuk LM; Tavares FX; Wells-Knecht KJ; Willard DH; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2005 Aug; 15(15):3540-6. PubMed ID: 15982880
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2004 Oct; 14(19):4897-902. PubMed ID: 15341947
[TBL] [Abstract][Full Text] [Related]
6. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
[TBL] [Abstract][Full Text] [Related]
7. A structural screening approach to ketoamide-based inhibitors of cathepsin K.
Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Wells-Knecht KJ; Wright LL
Bioorg Med Chem Lett; 2005 May; 15(9):2209-13. PubMed ID: 15837295
[TBL] [Abstract][Full Text] [Related]
8. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.
Barrett DG; Catalano JG; Deaton DN; Long ST; Miller LR; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2004 May; 14(10):2543-6. PubMed ID: 15109647
[TBL] [Abstract][Full Text] [Related]
9. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
[TBL] [Abstract][Full Text] [Related]
11. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
12. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
[TBL] [Abstract][Full Text] [Related]
13. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.
Setti EL; Davis D; Janc JW; Jeffery DA; Cheung H; Yu W
Bioorg Med Chem Lett; 2005 Mar; 15(5):1529-34. PubMed ID: 15713422
[TBL] [Abstract][Full Text] [Related]
14. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
Crane SN; Black WC; Palmer JT; Davis DE; Setti E; Robichaud J; Paquet J; Oballa RM; Bayly CI; McKay DJ; Somoza JR; Chauret N; Seto C; Scheigetz J; Wesolowski G; Massé F; Desmarais S; Ouellet M
J Med Chem; 2006 Feb; 49(3):1066-79. PubMed ID: 16451072
[TBL] [Abstract][Full Text] [Related]
15. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.
Marquis RW; Yamashita DS; Ru Y; LoCastro SM; Oh HJ; Erhard KF; DesJarlais RL; Head MS; Smith WW; Zhao B; Janson CA; Abdel-Meguid SS; Tomaszek TA; Levy MA; Veber DF
J Med Chem; 1998 Sep; 41(19):3563-7. PubMed ID: 9733481
[No Abstract] [Full Text] [Related]
16. Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.
Robichaud J; Bayly C; Oballa R; Prasit P; Mellon C; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB
Bioorg Med Chem Lett; 2004 Aug; 14(16):4291-5. PubMed ID: 15261289
[TBL] [Abstract][Full Text] [Related]
17. A cytochemical assay for osteoclast cathepsin K activity.
Dodds RA
Cell Biochem Funct; 2003 Sep; 21(3):231-4. PubMed ID: 12910475
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in cathepsin K inhibitor design.
Grabowskal U; Chambers TJ; Shiroo M
Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
[TBL] [Abstract][Full Text] [Related]
19. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
20. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
